// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Optimization of biologic tapering using ultrasound in ra patients

S. Bawa - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Organ damage in systemic lupus erythematosus is consistently associated with increased mortality: a meta-analysis

E.R. Hammond - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Organ damage progression and long-term safety of belimumab (BEL in patients with systemic lupus erythematosus (SLE: an extension of pivotal phase 3 bliss studies

R.F. Van Vollenhoven - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Osteoporotic hip fractures in men: a rising concern

M. Sehgal - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

N/A

Outcomes that matter to people living with inflammatory arthritis; a global standard set, developed by the international consortium for health outcome measurement (ICHOM working group for inflammatory arthritis

M. Oude Voshaar - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Paediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA and microscopic polyangiitis (MPA

P. Brogan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Wegener's granulomatosis

Methylprednisolone

Palindromic rheumatism (PR: experience in a real world setting – the nottingham casemix register (NCR

F. Kynaston-Pearson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Participation in clinical trials has a positive impact on the psychological and employment well-being of patients with inflammatory arthritis

H Alkoky - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Patient involvement in respiratory research

C. Coleman - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

patient non-attendance characteristics at rheumatology outpatient clinics within a large multi-ethnic region

A. Takyi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patient reported outcome measures following knee and hip replacement for individuals with rheumatoid arthritis: evidence from routinely-collected data

E. Burn - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across europe

S.A. Just - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patient-based disease activity score predicts flare better than improvement – blood test provides insignificant contribution

M.-H. A. Leung - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patient-perceived involvement in disease management drives patient-physician alignment in satisfaction with disease control in psoriatic arthritis

L. Gossec - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Patient-reported outcomes with sarilumab in patients with rheumatoid arthritis are similar regardless of primary or secondary failure with tumour necrosis factor inhibitors

V. Strand - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Sarilumab

Patients presenting with new musculoskeletal symptoms in the wrists, hands and feet enriches detection of anti-ccp antibodies in primary care – a national cohort study

P. Pentony - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patients with rheumatoid arthritis and lupus have similar prevalence of periodontitis – a cross-sectional survey

C. Ciurtin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Patients with systemic sclerosis develop focal fibrosis over time, and increased ecv diffuse fibrosis seen in poor prognostic group – a first longitudinal cardiac mri study

R.B. Dumitru - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Pde4 inhibitor attenuation of il-23 secretion from mononuclear cells

C. Bridgewood - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

histamine

Perceptions of biosimilars among practicing rheumatologists: results from a multicountry study in europe

C. Karki - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved